Arvinas And Pfizer’s Protein Degrader Shows Mixed Results In Breast Cancer
Data Accidentally Released Ahead Of Congress
The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.
